Document is current

Any future updates will be listed below

Metastasiertes triple-negatives Mammakarzinom: Überlebensvorteil mit Sacituzumab Govitecan

Crossref DOI link: https://doi.org/10.1007/s15013-022-4445-6

Published Online: 2022-07-08

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark